首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1604501

腫瘤學人工智慧 (AI) 市場：未來預測（2024-2029）

Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029

出版日期: 2024年10月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

腫瘤人工智慧（AI）市場預計將以 35.43% 的複合年成長率成長，到 2029 年，市場規模將從 2024 年的 19.63 億美元增至 89.44 億美元。

在人工智慧 (AI) 的幫助下，腫瘤學領域正在取得令人難以置信的突破。人工智慧的多重好處正在推動人工智慧在癌症研究中的日益普及，從而推動腫瘤學市場的人工智慧。此外，癌症患者的盛行率增加，加上人口老化和癌症風險的增加，預計也將推動該市場的發展。此外，市場參與者的研究計劃以及對人工智慧整合和產品發布的資助正在進一步推動人工智慧在腫瘤學領域的發展。

此外，人工智慧相關醫療設備的產品核可數量不斷增加預計也將加速市場擴張。例如，美國FDA核准的DermaSensor 是截至 2024 年 1 月第一個檢測皮膚癌的人工智慧醫療設備。

人工智慧在癌症治療中的未來應用具有革命性的潛力，包括精準醫療、早期檢測和單獨設計的治療方法。這可能會徹底改變癌症的診斷和治療，因為人工智慧可以在查看複雜的資料集時發現微妙的模式並提供即時見解。這個新時代有望改善患者的治療結果和醫療保健服務。

腫瘤學人工智慧 (AI) 市場促進因素

腫瘤學人工智慧的優勢有助於市場成長

腫瘤學人工智慧的關鍵成長要素是將人工智慧納入癌症研究中可以獲得的許多好處。例如，人工智慧演算法可以掃描乳房 X 光檢查、電腦斷層掃描和 MRI 影像，以尋找癌症的早期症狀。在這一領域，演算法經常識別人類放射科醫生可能錯過或遺漏的模式和異常值，從而有可能實現早期診斷並改善預後。對於腫瘤學家來說，人工智慧可以深入研究從患者資料、病歷到臨床指南的所有內容，以幫助制定治療計劃。

基於患者體型、位置和個性等因素，基於人工智慧的演算法將能夠推薦最佳治療途徑。如有必要，人工智慧模型可以進一步分析患者臨床記錄和治療史的資料，以預測疾病發作、治療反應和預後。

腫瘤學人工智慧 (AI) 市場的地理格局

北美在預測期內將經歷指數級成長

預計在預測期內，北美將佔據腫瘤人工智慧市場的重要佔有率。腫瘤學人工智慧的推出正在降低癌症治療的總體成本，而不影響治療質量，預計將對北美市場產生積極影響。促成這一成長的因素包括癌症患者數量的增加、人口老化、醫療保健領域的強大影響力以及人工智慧的採用。例如，根據美國癌症協會的數據，癌症是美國第二大死因，2022 年約有 190 萬例病例和 6,090,360 人因癌症死亡。根據同一消息來源，美國成長最快的年齡層是 85 歲及以上的成年人。此外，Azra AI、IBM 和英特爾公司等大公司預計將透過其技術進步推動腫瘤人工智慧市場。

為什麼要購買這份報告？

富有洞察力的分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業明智以及其他子區隔。
競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
市場促進因素和未來趨勢：探索動態因素和關鍵市場趨勢以及它們將如何塑造未來市場發展。
可行的建議：利用洞察力做出策略決策，在動態環境中發現新的業務流和收益。
受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業與市場考量、商機評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

分析範圍

歷史資料與預測（2022-2029）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
競爭對手定位、策略和市場佔有率分析
收益成長率與預測分析：按細分市場/地區（按國家）
公司概況（策略、產品、財務資訊、主要趨勢等）

介紹
北美洲
- 依組件類型
- 按癌症類型
- 按治療類型
- 按國家/地區
南美洲
- 依組件類型
- 按癌症類型
- 按治療類型
- 按國家/地區
歐洲
- 按組件類型
- 按癌症類型
- 按治療類型
- 按國家/地區
中東/非洲
- 按組件類型
- 按癌症類型
- 按治療類型
- 按國家/地區
亞太地區
- 按組件類型
- 按癌症類型
- 按治療類型
- 按國家/地區

第9章競爭環境及分析

主要企業及策略分析
市場佔有率分析
企業合併(M&A)、協議與合作
競爭對手儀表板

第10章公司簡介

Azra AI
IBM
Siemens Healthcare GmbH
Intel Corporation
GE HealthCare
NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI

簡介目錄

Product Code: KSI061615764

The Artificial Intelligence (AI) in oncology market is expected to grow at a CAGR of 35.43%, reaching a market size of US$8.944 billion in 2029 from US$1.963 billion in 2024.

The oncology discipline has seen tremendous breakthroughs with the help of artificial intelligence (AI). Multiple advantages of AI are driving its increased adoption in cancer studies, thereby propelling AI in the oncology market. Moreover, the growing prevalence of cancer cases coupled with an aging population and their higher risk of cancer is also expected to boost this market. Additionally, market players' research initiatives and funds for AI incorporation and product launches are further aiding AI in the oncology market.

Additionally, growing product approval of medical devices linked to AI is projected to accelerate market expansion. For instance, the U.S. FDA-approved DermaSensor is the first AI medical device to detect skin cancer as of January 2024.

Future applications of AI in cancer care would hold revolutionary promise and include precision medicine, early detection, and individually designed treatment regimens. This can completely change cancer diagnosis and treatment, as AI can spot minute patterns when viewing complex dataset moats and giving real-time insights. With such a new epoch, better patient outcomes and healthcare delivery would emerge.

Artificial intelligence (AI) in oncology market drivers

Advantages of AI in Oncology is contributing to its market growth

A major growth driver of AI in the oncology market is the many benefits of including AI in cancer studies. For instance, AI algorithms can scan mammograms, CT scans, or MRI images for early symptoms of cancer. This area is where algorithms frequently identify patterns and outliers that human radiologists may not see or even miss, thus leading to earlier diagnosis and possibly better outcomes. For oncologists, AI would peruse everything, from patient data and medical history to clinical guidelines, in support of the design of a treatment plan.

Based on factors such as the size, site, and character of patients, AI-based algorithms would be capable of recommending optimum pathways in treatment. AI models, if needed, can further analyze data from patient clinical records and treatment histories to predict the development of an illness, treatment response, and prognosis.

Artificial intelligence (AI) in oncology market geographical outlook

North America is witnessing exponential growth during the forecast period

The North American region is expected to hold a significant share of AI in the oncology market during the forecasted period. The launch of AI for oncology has reduced overall cancer treatment costs without affecting the quality of treatment, which is anticipated to positively impact the North American market. Various factors attributed to this growth are rising cancer cases, an aging population, a strong healthcare presence, and the adoption of AI. For example, cancer is the second-most leading cause of death in the US, as per the American Cancer Society, with around 1.9 million cases in 2022 and 6,09,360 cancer deaths in the country. As per the same source, the fastest-growing age group in the US is adults over 85. Moreover, major market players such as Azra AI, IBM, and Intel Corporation are further expected to propel AI in the oncology market through technological advancements.

Reasons for buying this report:-

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data & forecasts from 2022 to 2029
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The artificial intelligence (AI) in oncology market is segmented and analyzed as follows:

By Component Type

Software Solutions
Hardware
Services

By Cancer Type

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others

By Treatment Type

Chemotherapy
Radiotherapy
Immunotherapy
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings
3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY COMPONENT TYPE

5.1. Introduction
5.2. Software Solutions
5.3. Hardware
5.4. Services

6. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY CANCER TYPE

6.1. Introduction
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Prostate Cancer
6.5. Colorectal Cancer
6.6. Brain Tumor
6.7. Others

7. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY TREATMENT TYPE

7.1. Introduction
7.2. Chemotherapy
7.3. Radiotherapy
7.4. Immunotherapy
7.5. Others

8. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Component Type
- 8.2.2. By Cancer Type
- 8.2.3. By Treatment Type
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Component Type
- 8.3.2. By Cancer Type
- 8.3.3. By Treatment Type
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Component Type
- 8.4.2. By Cancer Type
- 8.4.3. By Treatment Type
- 8.4.4. By Country
  - 8.4.4.1. United Kingdom
  - 8.4.4.2. Germany
  - 8.4.4.3. France
  - 8.4.4.4. Spain
  - 8.4.4.5. Others
8.5. Middle East and Africa
- 8.5.1. By Component Type
- 8.5.2. By Cancer Type
- 8.5.3. By Treatment Type
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Israel
  - 8.5.4.4. Others
8.6. Asia Pacific
- 8.6.1. By Component Type
- 8.6.2. By Cancer Type
- 8.6.3. By Treatment Type
- 8.6.4. By Country
  - 8.6.4.1. Japan
  - 8.6.4.2. China
  - 8.6.4.3. India
  - 8.6.4.4. South Korea
  - 8.6.4.5. Indonesia
  - 8.6.4.6. Thailand
  - 8.6.4.7. Others